Misra VP, et al. - The researchers aimed to describe the baseline characteristics of this larger and longer study (INTEREST IN CD2 study) documenting the effect of botulinum neurotoxin type A (BoNT-A) treatment upon long-term patient satisfaction with respect to the control of symptoms associated with idiopathic cervical dystonia (CD). In this study, they provided sizeable data regarding the epidemiology and clinical presentation of CD and showed an international heterogeneity of clinical practice.

Methods

• INTEREST IN CD2 represented a prospective, international, 3-year, longitudinal, observational study following the course of adult idiopathic cervical dystonia (CD) treated with botulinum neurotoxin type A (BoNT-A).
• The primary objective of this study was to document long-term patient satisfaction with BoNT-A treatment.
• The researchers here reported baseline data.

Results

• A total of 1036 subjects (67.4% of subjects were female; mean age was 54.7 years old; mean TWSTRS Total score was 31.7) were included in this study.
• In this study, BoNT-A injections were usually given in line with BoNT-A prescribing information.
• Splenius capitis (87.3%), sternocleidomastoid (82.6%), trapezius (64.3%), levator scapulae (40.9%) and semispinalis capitis (26.9%) were the most commonly injected muscles.
• Using a guidance technique, 35.5% of subjects were injected.
• Most subjects (87.8%) had been previously treated with BoNT-A (median interval between last pre-study injection and study baseline was 4 months).
• Among these, 84.8% subjects reported satisfaction with BoNT-A treatment at peak effect during their previous treatment cycle and 51.5% remained satisfied at the end of the treatment.
• Analyses by geographical region showed heterogeneity in the clinical characteristics and BoNT-A injection practice of CD subjects presenting for routine treatment.